XM does not provide services to residents of the United States of America.
G
G

GSK


News

German Cartel Office: GSK Cleared To Buy Curevac Assets

BRIEF-German Cartel Office: GSK Cleared To Buy Curevac Assets July 12 (Reuters) - CureVac NV 5CV.DE : GERMAN CARTEL OFFICE: GSK CLEARED TO BUY CUREVAC ASSETS Source text Further company coverage: 5CV.DE
G

GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season

BRIEF-GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season July 11 (Reuters) - GSK plc GSK.L : GSK BEGINS SHIPPING INFLUENZA VACCINE DOSES FOR 2024-25 SEASON GSK: EXPECTS TO DISTRIBUTE OVER 36 MILLION DOSES OF ITS TRIVALENT INFLUENZA VACCINES IN US THIS SEASON Source text for Eikon: ID:nBw7xSr4xa Further company coverage: GSK.L
G

Diageo, Publicis, Wolters Kluwer NV

EUROPE RESEARCH ROUNDUP-Diageo, Publicis, Wolters Kluwer NV July 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Diageo, Publicis and Wolters Kluwer NV, on Thursday. HIGHLIGHTS * Diageo DGE.L : HSBC cuts target price to 3,300p from 3,500p * Mfe-Mediaforeurope NV MFEB.MI : JP Morgan raises to overweight from neutral * Prosiebensat 1 Media SE PSMGn.DE : JP Morgan raises to overweight from neutral * Publicis PUBP.PA : JP Morgan cuts
A
A
A
B
C
C
D
D
D
D
E
E
G
H
K
L
P
R
S
S
V
A
A
A
A
B
D
G
J
W

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births By Christy Santhosh July 8 (Reuters) - Pfizer's PFE.N respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots. The vaccine Abrysvo was approved by the U.S.
G
P

Top of the Street: GSK, Melrose Industries, Arkema, B&M

BUZZ-Top of the Street: GSK, Melrose Industries, Arkema, B&M A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Five-star ranked RBC Capital Market's analyst Mark Fielding raises Melrose Industries MRON.L to "outperform" from "sector perform", seeing fundamentals remaining very supportive despite shares underperforming in the past months, and expecting further earnings upgrades ** J.P.Morgan raises Arkema AKE.PA to "neutral" from "underweight", seeing buysi
A
G

Glencore, Rio Tinto, Michelin

EUROPE RESEARCH ROUNDUP-Glencore, Rio Tinto, Michelin July 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Rio Tinto and Michelin, on Monday. HIGHLIGHTS * Arkema SA AKE.PA : JP Morgan raises to neutral from underweight * Glencore GLEN.L : Jefferies raises target price to 600p from 550p * Michelin MICP.PA : HSBC raises to buy from hold * Pirelli & C SpA PIRC.MI : HSBC raises to buy from hold * Rio Tinto RIO.L : Jefferies
A
A
A
A
A
B
B
B
C
C
D
G
G
H
L
A
D
P
R

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

British Business - July 4

PRESS DIGEST-British Business - July 4 July 4 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Dublin-based video game services group Keywords Studios KWS.L has agreed to a bid worth 2.2 billion pounds ($2.80 billion) from European private equity firm EQT EQTAB.ST - A partnership between GSK GSK.L and CureVac 5CV.DE struck during the pandemic has been restructured i
G

Financial Times - July 4

PRESS DIGEST- Financial Times - July 4 July 4 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - EQT strikes 2.2 bln STG deal for Irish video gaming group Keywords Studios - Hawksmoor restaurant chain up for sale - Germany vetoes sale of sensitive turbine unit to Chinese group - GSK signs 1.4 bln euros mRNA vaccine deal with troubled biotech CureVac Overview - A consortium led by Swedish
G
P
V

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Quest Diagnostics, Lufthansa, CoinDCX Updates: Volkswagen July 3 (Reuters - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday: ** Quest Diagnostics DGX.N said it would acquire Canada-based LifeLabs from pension plan owner OMERS for about C$1.35 billion, or about $985 million, including net debt.
G
L
P
P
V
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions July 3 (Reuters - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Wednesday: ** Germany's cabinet blocked the planned sale of Volkswagen VOWG_p.DE subsidiary MAN Energy Solutions' gas turbine division to a Chinese company, two government sources said. nS8N3IC08R ** A joint venture between Trafigura and the Frontier Group of Companies (FGC) has completed its acquisition of the Mountain Creek power plant from a group of
G
P
P
V
U

CureVac soars on COVID, influenza vaccines deal with GSK

BUZZ-CureVac soars on COVID, influenza vaccines deal with GSK ** Frankfurt-listed shares in CureVac 5CV.DE jump around 24% after British drugmaker GSK GSK.L said it will take control of several vaccines the two companies were jointly developing ** GSK said it will pay CureVac 400 million euros ($430.12 million) upfront and up to an additional 1.05
G

UK Stocks-Factors to watch on July 3

UPDATE 1-UK Stocks-Factors to watch on July 3 Adds new items, updates futures July 3 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0 .7%. * GSK: GSK GSK.L has bought from CureVac 5CV.DE , CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said.
G
V

GSK buys COVID, influenza vaccines from retrenching CureVac

UPDATE 3-GSK buys COVID, influenza vaccines from retrenching CureVac Adds details on CureVac throughout July 3 (Reuters) - British drugmaker GSK GSK.L on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the German biotech company's financial lifeline.
G

Gsk Gsk And Curevac Collaboration Restructured

BRIEF-Gsk PLC - Gsk And Curevac Collaboration Restructured GSK plc GSK.L : GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED GSK PLC - ACQUIRES FULL RIGHTS TO DEVELOP VACCINES GSK - CUREVAC RECEIVES EUR 400 MILLION UPFRONT AND UP TO AN ADDITIONAL EUR 1.05 BILLION GSK - GSK WILL ASSUME FULL CON
G

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK buys full rights to make COVID, influenza vaccines from CureVac July 3 (Reuters) - GSK GSK.L has bought the full rights to develop and manufacture mRNA-based candidate vaccines for influenza and COVID-19 from CureVac for up to 1.05 billion euros ($1.13 billion), it said on Wednesday. GSK and CureVac started collaborating in 2020 to develop mRNA-based vaccines for infectious diseases.
G

Health Rounds: Weight gain from various antidepressants varies slightly

Health Rounds: Weight gain from various antidepressants varies slightly Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid July 2 (Reuters) - Hello Health Rounds Readers! Antidepressants have long been associated with weight gain, but today we have a study that finds little difference among a wide variety of the drugs.
G

US drugmakers fall as Biden urges price cuts on obesity drugs

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.
A
G
P
R

UK Stocks-Factors to watch on July 2

UPDATE 1-UK Stocks-Factors to watch on July 2 Adds new items, updates futures July 2 - Britain's FTSE 100 .FTSE index is seen opening lower on Tuesday, with futures FFIc1 down 0 .5%. * GSK: A Delaware judge rebuffed a request by GSK GSK.L and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward.
G
R

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge By Brendan Pierson July 1 (Reuters) - A Delaware judge rebuffed a request by GSK GSK.L and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward. The ruling by Judge Vivian Medinilla of the Delaware Superior Court means that the drugmakers, which also include Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, will have to ask the Delaware Su
G
P
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.